Login to Your Account

Other News To Note

Wednesday, March 23, 2011
Tesaro Inc., of Boston, announced that it signed an agreement with Amgen Inc., of Thousand Oaks, Calif., that grants Tesaro exclusive worldwide rights for the development, manufacture, commercialization and distribution of small-molecule inhibitors of anaplastic lymphoma kinase (ALK). Tesaro said it plans to develop one or more compounds for oncology indications, including the treatment of patients with non-small-cell lung cancer whose tumors are ALK-positive.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription